News | Atrial Fibrillation | May 19, 2020

Atrial Fibrosis Predicts Recurrent Stroke or New AF Onset 

HRS late-breaking study found predictors in patients with embolic stroke of undetermined source

Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,

May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking study at the Heart Rhythm Society (HRS) 2020 Science virtual meeting hypothesized ESUS patients with advanced atrial disease are at higher risk for recurrent stroke or incident atrial fibrillation (AF).

The study found ESUS patients with fibrosis, about 12 percent, had a significantly higher proportion of the combined outcome of recurrent stroke or new AF compared to those with fibrosis , less than 12 percent (5 vs. 22.6%; p=0.045).

Patients with ESUS have atrial fibrosis comparable to that seen in AF. Atrial fibrosis in about 12% may help identify ESUS patients who may benefit from anticoagulation for secondary prevention, said Nazem Akoum, M.D., MS, FHRS, attending physician, University of Washington Medical Center, Heart Institute of Edmonds, Seattle. He presented the study "Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study," at HRS. 

Researchers quantified atrial fibrosis using late-gadolinium enhancement MRI. Atrial fibrosis was reported as a percentage of the left atrial wall volume and compared across various groups: healthy controls, lacunar stroke, ESUS and known AF with or without prior stroke. They followed ESUS patients prospectively for 30 months for recurrent ischemic stroke or new AF.

The study enrolled 201 patients, 101 without AF: 35 healthy controls, 15 lacunar strokes, 51 patients with ESUS; and 100 patients with AF: 50 with prior stroke and 50 without prior stroke. Atrial fibrosis was significantly higher in ESUS compared to lacunar stroke patients (14.69±6.39% vs. 10.76±8.30; p = 0.02) and to healthy controls (8.1±7.9%; <0.0001). ESUS patients had comparable fibrosis to patients with AF with (17.9±11.4%) or without prior stroke (16.6±9.2%; p=NS for both) (Figure 1). In prospective follow up of ESUS, 5 patients (9.8%) had recurrent stroke and 5 had incident AF (9.8%). 

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Related Content

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial. #ESC #ESCcongress
News | Atrial Fibrillation | September 13, 2021
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate contro
The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
September 8, 2021 — Continuous heart rhythm monitoring – with...
The Adagio Medical iCLAS cryoablation system is commercial in Europe and is also part of an ongoing FDA IDE trial in the U.S. #HRS21
News | Atrial Fibrillation | August 09, 2021
August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up